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ABSTRACT
Cytomegalovirus (CMV) is a major cause of morbidity, costs and even mortality in organ
transplant recipients. CMV may also enhance the development of chronic allograft
nephropathy (CAN), which is the most important cause of graft loss after kidney
transplantation. The evidence for the role of CMV in chronic allograft nephropathy is
somewhat limited, and controversial results have also been reported.
The aim of this study was to investigate the role of CMV in the development of CAN,
and also to study the pathogenetic mechanisms behind this suggested association.
Material for the purpose of this study was available from altogether 70 kidney transplant
recipients who received a kidney transplant between the years 1992-2000. CMV infection
was diagnosed with pp65 antigenemia test or by viral culture from blood, urine, or both.
The presence of CMV in the kidney allograft biopsies was demonstrated by
immunohistochemical detection of CMV pp65 protein, or by DNA hybridization in situ.
Cytokines, adhesion molecules, and growth factors were demonstrated from allograft
biopsies by immunohistochemistry, and from urinary samples by ELISA-methods. CMV
infection and the presence of CMV in the allograft was correlated to histological changes
in the 6-month protocol biopsies, levels of adhesion molecules and growth factors, and to
long-term allograft function and survival during the five year follow-up.
CMV proteins were detectable in the 6-month protocol biopsies from 18/41 recipients
with evidence of CMV infection. In the histopathological analysis of the 6-month
protocol biopsies, presence of CMV in the allograft together with a previous history of
acute rejection episodes was associated with increased arteriosclerotic changes in small
arterioles, compared to recipients with no evidence of CMV infection after
transplantation.
In urinary samples collected during CMV infection, excretion of TGF-  was significantly
increased compared to recipients with no evidence of CMV infection. In recipients with
increased urinary excretion of TGF- , increased interstitial fibrosis was recorded in the 6-
month protocol biopsies.
In biopsies taken after an active CMV infection, CMV persisted in the kidney allograft in
17/48 recipients, as CMV DNA or antigens were detected in the biopsies more than 2
months after the last positive finding in blood or urine. This persistence was associated
with increased expression of TGF- , PDGF, and ICAM-1 and with increased vascular
changes in the allografts. Graft survival and graft function one and two years after
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transplantation, as measured by estimated glomerular filtration rate, was reduced in
recipients with persistent intragraft CMV. Persistent intragraft CMV infection was also a
risk factor for reduced graft survival in Cox regression analysis, and an independent risk
factor for poor graft function one and two years after transplantation in logistic regression
analysis. No differences were recorded in the number of CMV seronegative recipients
receiving an organ from a CMV seropositive donor, or in the number of acute rejection
episodes between the study groups.
In conclusion, these results show that persistent intragraft CMV infection is detrimental
to kidney allografts, causing increased expression of growth factors and increased
vascular changes, leading to reduced graft function and survival. One possible link to this
association could be the increased expression of the profibrotic and vasculopathic
molecule TGF- , observed in our study during both acute and persistent CMV infections.
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REVIEW OF THE LITERATURE
1. KIDNEY TRANSPLANTATION
The first successful kidney transplantation was performed in 1954 between identical
twins in Boston, USA [Murray et al. 1958]. Since the introduction of immunosuppressive
drugs, and especially cyclosporine in the late 1970s [Kahan et al. 1985], kidney
transplantation has become the standard curative treatment for end-stage renal disease. It
is cost-effective, improves quality of life and is highly beneficial for patient survival
compared to maintenance dialysis therapy [Wolfe et al. 1999, Cameron et al. 2000,
Winkelmayer et al. 2002]. Since 1964, almost 5000 kidneys have been transplanted in
Finland, and approximately 150-190 kidney transplantations are performed annually
[Salmela and Kyllonen 2004]. The most important primary renal disease causing kidney
transplantation in Finland is diabetic nephropathy, which is constantly increasing in
number. Other major causes for transplantation in Finland include various
glomerulonephritises and polycystic kidney disease. Worldwide, the most important
cause of renal transplantation is glomerular diseases, followed by diabetic nephropathy
[U.S. Department of Health and Human Services 2005, ERA-EDTA Registry 2005].
The results of kidney transplantation have been improving significantly over the past
decades. According to the Finnish transplant registry data, the overall 1-year graft
survival is nowadays approximately 93%, and graft half-life is more than 20 years
[Salmela and Kyllonen 2004] (Figure 1), whereas in the United States, 1- year graft
survival in cadaveric kidneys is approximately 89 % and graft half-life more than 10
years [U.S. Renal Data System 2005]. To prevent rejection, patients have to receive life-
long immunosuppressive medication after transplantation. Triple- drug
immunosuppression with cyclosporine, mycophenolate mofetil and methylpredisolone is
the standard regimen in Finland nowadays, with high immunological risk patients
receiving tacrolimus instead of cyclosporine.
11
Figure 1. Graft survival and graft half-life estimates for 1-year survivors from different
time periods in Helsinki (N=2445). Reprinted from Salmela and Kyllönen 2004, with
permission from the authors and the publisher (Elsevier).
Important complications early after transplantation include hyperacute rejection, delayed
graft function or primary nonfunction, renal arterial or vein thrombosis, and urinary tract
complications. After the first weeks post transplantation, the most important
complications are rejection and infections. Acute rejection develops in approximately
20% of kidney transplant recipients in Finland [Salmela and Kyllönen 2004] and is
mostly reversible when treated with high-dose intravenous corticosteroids, or the
administration of OKT3. The most important pathogens in immunocompromised organ
transplant recipients are herpesviruses, especially cytomegalovirus (CMV), other viruses,
and pneumocystis carinii.
Although the short-term results of kidney transplantation have improved greatly during
the past decades, the long- term results have not improved accordingly [Meier-Kriesche
et al. 2004]. The most important threats to long-term allograft success are death from
vascular, malignant or infectious cause, and loss of allograft from chronic allograft
dysfunction, often histologically defined as chronic allograft nephropathy [Chapman et
al. 2005]. The third common cause of renal allograft loss, after death with a functioning
graft and chronic allograft nephropathy, is recurrent glomerulonephritis in the allograft
[Briganti et al. 2002].
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2. CHRONIC ALLOGRAFT NEPHROPATHY
2.1. Terminology
The term “chronic allograft nephropathy” (CAN) was introduced in the 1990s to replace
the term “chronic rejection”, since also non-alloimmune risk factors contribute to this
process of allograft deterioration [Solez et al. 1993]. “Chronic rejection” applies only to
the alloantigen-dependent mechanisms of chronic changes in the graft, and should be
limited only to describe true alloimmune injury [Racusen et al. 1999]. The term “Chronic
renal allograft dysfunction” (CRAD) is commonly also used to describe this same process
but it is not a synonym of CAN. Chronic allograft nehropathy can be diagnosed only by
kidney transplant biopsies and is the histopathological picture seen in transplanted
kidneys. CAN represents the common pathway for renal allograft damage and is often
associated with allograft dysfunction. Histological changes, however, are often seen in
protocol biopsies before deterioration of allograft function; CRAD is thus always
associated with CAN, whereas CAN may precede the development of CRAD [Kreis and
Ponticelli 2001]. Chronic renal allograft dysfunction is therefore the functional
consequence of chronic allograft nephropathy.
The use of CAN to describe all the processes leading to allograft dysfunction has also
been criticized, since it may inhibit the goal to a specific diagnosis and appropriate
therapy, and “has little value other than hide our ignorance” [Colvin 2003].
2.2. Clinical and histological findings
The pathogenesis of CAN is incompletely understood, but it is thought to result from
various injuries to the allograft [Racusen et al. 1999] and several risk factors have been
identified. There is no effective treatment currently available for CAN, mostly because
histological signs of CAN represent late and irreversible damage. CAN ultimately leads
to chronic renal allograft dysfunction and graft loss; together with death with a
functioning graft, it is the most important reason for graft loss in the long-term,
representing a major limitation to kidney transplant long-term success [Paul 1999,
Chapman et al. 2005].
The earliest signs of CAN can be seen already after the first months post- transplantation
[Seron et al. 2002], and evidence reports the prevalence of histological changes
attributable to CAN being between 60- 70 % two years post transplantation [Solez et al.
1998]. In a study by Nankivell et al, all biopsies showed features of CAN five years after
transplantation, and at 10 years severe CAN was present in nearly 60% of grafts
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[Nankivell et al. 2003]. Clinically CAN is characterized by a slow rate of decline in
kidney function, also hypertension and proteinuria may be present [Paul 1999].
The international Banff scheme and classification provide tools for the scoring of
histopathological changes attributable to both acute rejection and chronic changes [Solez
et al. 1993, Racusen et al. 1999, Racusen et al. 2003]. The most important
histopathological findings in CAN are interstitial fibrosis and tubular atrophy [Racusen et
al. 1999, Chapman et al. 2005]. Vascular findings in CAN include fibrointimal thickening
in arteries and arterioles and arteriolar hyalinosis. The Banff scheme also describes
specific vascular findings caused by true chronic rejection by alloimmune mechanisms:
disruptions of the elastica, inflammatory cells in the vascular intima, proliferation of
myofibroblasts in the intima and the formation of neointima. Glomerular changes in CAN
are described as double contours in capillary loops, glomerular mesangial matrix increase
and ultimately glomerular sclerosis. The natural history of CAN has been described
recently [Nankivell et al. 2003]. During the first year after transplantation, the
histological picture is characterized by rapidly increasing interstitial fibrosis and tubular
atrophy, which are also the histopathological changes least sensitive to sampling errors;




The most important risk factor for the development of CAN is thought to be acute
rejection episodes [Almond et al. 1993, Lindholm et al. 1993, Meier-Kriesche et al.
2000]. According to the Banff ’97 classification, acute cellular rejection is histologically
classified as borderline (mild tubulitis and mild interstitial inflammation),
tubulointerstitial rejection without arteritis (type Ia moderate and type Ib severe), vascular
rejection (type IIa mild-to-moderate intimal arteritis, type IIb severe intimal arteritis) and
severe rejection (type III transmural arteritis and fibrinoid or smooth muscle necrosis)
[Racusen et al. 1999]. Recently, antibody mediated rejection was added to the Banff
scheme, identified as positive C4d deposits in peritubular capillaries or immunoglobulin
and complement in fibrinoid necrosis, together with serologic evidence of circulating
antibodies to donor HLA [Racusen et al. 2003].
Risk of CAN increases with the number of acute rejection episodes, and the intensity and
type of rejection have also been shown to be important [Matas et al. 1994]. Vascular
rejection is a more serious form of rejection and is more harmful to the graft [van Saase
et al. 1995], and acute antibody mediated rejection has been associated with poor
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prognosis compared to acute cellular rejection [Herzenberg et al. 2002]. Furthermore, late
acute rejections occurring months or years after transplantation are associated with a
greater risk of graft loss compared to early acute rejection episodes [Sijpkens et al. 2003].
2.2.2. Other immunological risk factors
Increased number of mismatched MHC antigens is strongly associated with inferior graft
survival [Held et al. 1994, Opelz et al. 1999]. The exact independent role of HLA-
mismatches is, however, somewhat questionable, since the logistics of HLA-matching
and organ allocation in areas of long geographic distances increase cold ischemia times
[Schnitzler et al. 1999]. Although contradictory views have also been expressed [Starzl et
al. 1995, Terasaki et al. 1995], HLA- matching is still regarded as important in increasing
the long-term prognosis of kidney allografts [Opelz et al. 1999, Opelz 2001]. Also
previous sensitization and the presence of preformed antibodies at the time of
transplantation, or development of HLA antibodies after transplantation, present a risk for
CAN [Terasaki 2003, Terasaki and Ozawa 2004, Hourmant et al. 2005].
2.2.3. Non- immunological risk factors
Delayed graft function is usually defined as the need for postoperative dialysis during the
first week after transplantation. It is thought to result from ischemia-reperfusion injury,
which triggers an inflammatory response, leading to increased immunogenicity and the
risk of early acute rejection [Perico et al. 2004]. The terms acute tubular necrosis and
delayed graft function are often used to define the same disorder, although they are not
synonyms: acute tubular necrosis is a histopathological diagnosis and can also occur in a
functioning graft, whereas delayed graft function is a clinical diagnosis. Delayed graft
function is thought to increase the risk of CAN [Shoskes and Cecka 1998, Perico et al.
2004]. Increased cold ischemia time is associated with a risk of DGF and acute rejection
episodes, and also with the development of CAN [Shoskes and Cecka 1998]. Whether
fully recovered delayed graft function in the absence of acute rejection episodes has any
effect on long-term allograft survival, is still a controversial issue, with evidence existing
in support of both hypotheses [Troppmann et al. 1996, Shoskes and Cecka 1998].
Increased donor age has a strong negative effect on graft function and survival after
transplantation [Terasaki et al. 1997]. Kidneys from older donors have suffered more
damage and have a smaller number of functional nephrons, and may have a reduced
capacity to repair damage adequately [Halloran et al. 1999]. Furthermore, many of the
histological changes associated with CAN are also seen in the aging kidney, such as
arteriolar hyalinosis, interstitial fibrosis, tubular atrophy, and glomerular sclerosis. Older
donor age increases the immunogenicity of the graft, resulting in more acute cellular
rejection episodes [de Fijter et al. 2001]. In addition, acute rejection episodes in old
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kidneys have a greater risk of progressing to graft loss [de Fijter et al. 2001]. Also very
young donor age is associated with a poorer prognosis after transplantation [Neumayer et
al. 1994]. Donor source is also a major contributor to long-term graft survival, since
grafts from living donors have a significantly longer half-life than cadaveric grafts from
brain-dead donors [Terasaki et al. 1995, Hariharan et al. 2000], although this may apply
only in the presence of acute rejection episodes [Knight et al. 2001].
Several classical risk factors for atherosclerosis may increase the risk of CAN, such as
hypercholesterolemia [Dimeny et al. 1995, Roodnat et al. 2000], hypertension [Opelz et
al. 1998], diabetes [Miles et al. 1998] and smoking [Sung et al. 2001]. Reduced renal
function at baseline and also decline of function during the first year are important
determinants of long- term graft survival, although that may only represent a previous
injury [Kasiske et al. 2002]. In epidemiological studies, several other risk factors for
CAN have also been identified, such as hypoalbuminemia, recipient young age, and
recipient black race [Massy et al. 1996, Young and Gaston 2000]. Infections caused by
cytomegalovirus (CMV) have also been associated with decreased graft survival [Nett et
al. 2004], although controversial evidence exists as well [Dickenmann et al. 2001].
3. OTHER CAUSES OF ALLOGRAFT DYSFUNCTION
3.1. Calcineurin inhibitor nephrotoxicity
After the introduction of cycloposporine (CsA) in the 1970s, calcineurin inhibitors (CNI)
have been the backbone of immunosuppression in kidney transplantation, enabling also
the transplantation of other solid organs. The immunosuppressive effect of CNI:s
cyclosporine and tacrolimus is based on the inhibition of the phosphatase calcineurin,
which plays a key role in T-cell activation [Kahan 1989]. Although the
immunosuppressive potential of CNI:s has resulted in improved early graft survival and
reduced acute rejection rates, a major concern for decades has been the nephrotoxicity of
both CsA and tacrolimus, although most of the research data is from cyclosporine [Calne
et al. 1978, Myers et al. 1984, Bennett et al. 1996, Finn 1999, Nankivell et al. 2004]. CsA
nephrotoxicity can be roughly divided into an acute form, which is reversible by reducing
the dose of CsA, and chronic nephrotoxicity, which is somewhat poorly documented but
is thought to be irreversible [Bennett et al. 1996, Burdmann et al. 2003]. Calcineurin
inhibitors cause injury to the kidneys by several mechanisms, such as renal
vasoconstriction and upregulation of fibrotic growth factors [Bennett et al. 1996, Khanna
et al. 2002, Burdmann et al. 2003]. Clinically CsA nephrotoxicity presents as impaired
renal function, electrolyte disturbances and hypertension. Histopathological
characteristics suggested to be specific for CsA nephrotoxicity include nodular arteriolar
hyalinosis, tubular microcalcification, isometric tubular vacualization, striped cortical
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fibrosis, peritubular and capillary congestion and juxtaglomerular hyperplasia [Bennett et
al. 1996]. The contribution of CsA nephrotoxicity to CAN is very difficult to estimate.
By definition, obvious CsA nephrotoxicity with specific histopathological characteristics
should be excluded from CAN [Halloran et al. 1999]. Some chronic lesions of CAN and
CsA nephrotoxicity, such as arteriolar hyalinosis and interstitial fibrosis, however, are
indistinguishable [Colvin 2003]. Whether CsA nephrotoxicity is a key player in the
progression of CAN, or whether adequate doses of CNIs protect against CAN remains
one of the major unknown issues in kidney transplantation [Halloran et al. 1999].
3.2. Infections
Infections are also able to cause allograft dysfunction. Bacterial urinary tract infections
after kidney transplantation are common and are able to cause graft dysfunction, but they
have also been associated with acute rejections [Tolkoff-Rubin and Rubin 1992, Yang et
al. 1994, Nampoory et al. 2003], although controversial evidence exists as well [Maki et
al. 1992]. Also other bacterial infections have been reported to be associated with graft
dysfunction, such as mycobacterial infections, respiratory tract infections and septicemia
[Schmaldienst and Horl 1997, Nampoory et al. 2003, Queipo et al. 2003, Moroni et al.
2004].
The most common viral infection after renal transplantation is caused by cytomegalovirus
(CMV) [Patel and Paya 1998]. CMV is able to cause graft dysfunction during acute
infection, and may be associated with long-term complications. The effects of CMV on
kidney transplants are described in detail below. Chronic kidney transplant dysfunction
can also be caused by polyomavirus hominis 1 virus, better known as BK virus (BKV),
infecting up to 90% of the general population. BKV replication is seen in 10-60% of
recipients after kidney transplantation, and BKV can cause ureteric stenosis, transient
graft dysfunction, or irreversible graft failure [Hirsch and Steiger 2003]. Evidence
indicates that polyomavirus associated nephropathy is seen in 1-10% of kidney allograft
recipients, and it leads to graft failure in 10-80% of cases [Hirsch et al. 2005]. Closely
related to BK virus is polyomavirus hominis 2 virus, JC virus, which also infects renal
transplants [Hirsch et al. 2005]. The clinical significance of JCV in transplant dysfunction
remains to be resolved.
4. PATHOGENESIS OF CAN
The pathogenesis of chronic allograft nephropathy is still not fully elucidated, although
several theories have been suggested [Hayry et al. 1993, Halloran et al. 1999, Paul 1999,
Joosten et al. 2004]. Chronic allograft nephropathy is thought to originate from a series of
challenges to the allograft. Injury to the graft begins even before the effect of the
alloresponse: donor brain death, warm ischemia, cold ischemia, and ischemia-
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reperfusion injury all result in increased immunogenicity in the graft, causing increased
inflammatory alloresponse after the revascularization of the allograft. Series of injuries
continues during the first weeks after transplantation; acute tubular necrosis, acute
rejection episodes, cyclosporine nephrotoxicity, and infections in the graft, among others,
contribute to the injury of the transplanted kidney. All this occurs against the background
of foreign MHC antigens and often in a kidney from an older donor with some extent of
age-associated changes and limited capacity of restoration from injury. Several
mechanisms have been suggested for the development of CAN. Alloimmune mechanisms
are thought to be central in the development of CAN. Renal injury is thought to result in
an inflammatory response; recipient lymphocytes and monocytes enter the graft and
produce cytokines, which stimulate inflammatory and mesenchymal cells to produce
excess growth factors, resulting in proliferation of myofibroblasts and smooth muscle
cells in the vascular wall and increased of collagen synthesis in fibroblasts. This process
is thought to lead to scar formation; excess interstitial fibrosis, tubular atrophy and
vascular intimal thickening represent the stereotypic histopathological picture seen in
end-stage renal diseases. Whether the initial injury in the graft occurs in the vascular
wall, resulting in the proliferation of the vascular wall and narrowing of the lumen,
followed by tubulointerstitial lesions due to growth factor response and partly ischemia
[Hayry et al. 1993], or whether the initial event is tubular cell injury, resulting in growth
factor response, tubular atrophy, interstitial fibrosis, and finally vascular narrowing, is
still under discussion [Paul 1999]. Recent description of the histopathological natural
history of CAN supports the latter hypothesis [Nankivell et al. 2003]. In their study,
interstitial fibrosis and tubular atrophy were the first manifestations of CAN and preceded
vasculopathic changes.
Most of the histopathological changes of CAN are also seen in the aging kidney. This fact
and knowledge of the limited cell cycle capacity has led to the theory that cellular or
tissue senescence might play a role in the pathogenesis of CAN [Halloran et al. 1999].
Continuous injury to an aging graft may result in exhaustion of the replicative cells and
inability to repair injury and remodel the tissue in an adequate way. This is thought to
lead to the histopathological lesions seen in CAN.
On the other hand, glomerular hyperfiltration due to decreased renal mass and smaller
number of functional nephrons after injuries to the graft, or perhaps also from severe
donor-recipient size mismatch, may contribute to the development of CAN [Paul 1999].
Severe persistent glomerular hypertension may lead to changes in glomerular
permeability and leakage of molecules, resulting in an increase in the glomerular
mesangium, ultimately leading to glomerulosclerosis. Changes in glomerular
permeability also may lead to leakage of proteins to the urine. Proteinuria is thought to
18
have a causative role in the development of tubulointerstitial damage, either by direct
tubular cell injury caused by albumin, or by a more complex process of growth factors in
the glomerular ultrafiltrate, stimulating tubular cells and causing interstitial fibrosis
[Hirschberg and Wang 2005]. Increasing evidence from the pathogenesis of renal fibrosis
in several primary fibrotic renal diseases highlights the importance of tubular cells as the
pivotal cells in renal fibrosis; tubular cells possess important secretory properties and in
fibrosis, increased number of fibroblasts derives from tubular cells by epithelial-
mesenchymal transition, also after kidney transplantation [Iwano and Neilson 2004,
Vongwiwatana et al. 2005]. Fibrosis is thought to represent a final physiological pathway
of renal damage regardless of the underlying primary cause [Chatziantoniou and
Dussaule 2005], and this could also apply to kidney transplant pathophysiology.
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Figure 2. Suggested mechanisms of the pathogenesis of chronic allograft nephropathy
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4.1. Alloresponse
The process of alloresponse begins in allorecognition, which can occur in two major
ways, by direct and indirect recognition. In the direct allorecognition pathway, recipient
T cells recognize intact foreign MHC antigens on the surface of donor-derived antigen
presenting cells that are also able to provide the necessary co-stimulation for T cell
activation. This direct pathway results mainly in cytotoxic CD8+ T cell response and
plays a role in early allograft rejection [Sayegh 1999]. In indirect allorecognition,
recipient-derived antigen presenting cells present fragments of donor-derived foreign
MHC-peptides, which they have phagocytized and processed to their MHC class II
surface molecule peptide-binding clefts, to recipient T cells. In the presence of the
necessary co-stimulatory molecules and cytokine milieu, T cells become activated. The
indirect pathway activates mostly CD4+ helper T cells. Evidence shows that the indirect
allorecognition pathway enhances acute rejection and is important in chronic alloimmune
response [Sayegh 1999].
Cytokines are secreted by different cell types, such as monocytes and T cells, especially
CD4+ T cells. Cytokines stimulate target cells by binding to their specific receptors on
the target cell surface and they can stimulate cells in an autocrine, paracrine, or endocrine
fashion. Proinflammatory cytokines increase inflammatory reaction by stimulating
inflammatory cells, such as T cells, B cells, and macrophages. They also increase MHC
expression on cell surfaces, stimulate the expression of adhesion molecules on epithelial
and endothelial cell surfaces, and also influence the synthesis of other cytokines, some of
which are also inhibitory to the process. The type of cytokine response determines the
type and intensity of immune response.
In the beginning of the immune response, proinflammatory cytokines, such as interferon-
gamma (IFN- ), interleukins -1 and -2 (IL-1 and IL-2) and tumor necrosis factor, direct
the immune response towards cell-mediated immune response (Th1). Th1 cells secrete
IL-2 and IFN- , which stimulate cytotoxic and delayed-type hypersensitivity response. In
contrast, Th2 cells secrete cytokines such as IL-4, IL-5, IL-6, and IL-10, which direct the
immune response towards antibody mediated immune response and inhibit cell-mediated
immune response [Dallman 2001]. Both cell-mediated immune response and humoral
response are thought to be important in the development of chronic changes in the graft
[Sayegh 1999, Terasaki 2003].
The role of alloimmune response is thought to be central in the development in CAN
[Joosten et al. 2004]. Although several non-immunological risk factors for CAN have
been described above, some of them, such as increased donor age and ischemia-
reperfusion injury, result in increased immunogenicity of the allograft, and the injury to
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the graft is thought to be mainly alloimmune mediated. The division between alloantigen-
dependent and independent risk factors is therefore somewhat arbitrary.
Adhesion molecules play a key role in the early phase of the alloimmune response. They
are mainly expressed on the surface of epithelial and endothelial cells, but also on antigen
presenting cells [Solez et al. 1997]. Entry of the inflammatory cells from the bloodstream
to the allograft is a complex process mediated by cytokines, chemotactic factors and
adhesion molecules. After rolling of leucocytes along the vessel wall, firm adhesion of
leucocytes to the vascular wall at the site of inflammation, and also transmigration of
leucocytes into the tissue, is mediated by adhesion molecules [Springer 1994]. Adhesion
molecules are also involved in T cell activation [Altmann et al. 1989, Lebedeva et al.
2005].
Expression of adhesion molecules is stimulated by proinflammatory cytokines, such as
tumor necrosis factor-alfa (TNF- ), IL-1 and IFN- , during the initiation of an
inflammatory process. The most important adhesion molecules in the context of allograft
rejection are thought to be intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1), and endothelial leucocyte adhesion molecule (ELAM-
1) and their ligands lymphocyte function associated antigen-1 (LFA-1), very late antigen-
4 (VLA-4), and Sialyl Lewis X (sLeX) expressed on leucocytes [Solez et al. 1997,
Fuggle and Koo 1998]. The expression of these adhesion molecules is increased during
acute renal allograft rejection in tubular, glomerular, and endothelial cells. Increased
expression of ICAM-1 and VCAM-1 has also been seen in chronic renal allograft
rejection [Hill et al. 1995]. Treatment with antibodies against adhesion molecules can
reverse or prevent acute rejection in animal models [Cosimi et al. 1990], although a large
clinical trial with anti-ICAM-1 monoclonal antibody showed no benefit after kidney
transplantation [Salmela et al. 1999], suggesting that actions of ICAM-1 can be overcome
by other components of the immune system.
4.2. Growth Factors
Proinflammatory cytokines produced by the inflammatory alloresponse stimulate several
cell types, both inflammatory and mesenchymal cells, to produce different growth factors
that are thought to lead to a repair process in response to the injury, and contribute to the
chronic changes seen in the graft. Several growth factors have been identified to be
important in the process of CAN.
4.2.1. Transforming growth factor-  (TGF- )
Transforming growth factor-  is a multifunctional cytokine thought to play a central role
in tissue fibrosis in different organs and different pathogenic states [Border and Noble
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1994]. TGF-  exists in three different isoforms, whose biological properties are very
similar. Most of the current data arise from TGF- 1, which is the most abundant isoform
in all tissues. It is secreted by platelets and various inflammatory cells in response to
injury, as an inactive precursor bound to a latency-associated peptide, and it requires
activation before exerting its biological effects. Expression of TGF-  is induced by
cytokines, such as IL-1 and TNF- , and also by autoinduction [Van Obberghen-Schilling
et al. 1988, Kim et al. 1990]. TGF-  directly stimulates the synthesis of several
extracellular matrix components, modulates the composition of the matrix, and inhibits
the degradation of extracellular matrix by blocking the secretion and functions of
proteases. Some of the growth stimulatory actions of TGF-  are executed via indirect
mechanisms, such as mesangial cell growth via the stimulation of platelet-derived growth
factor (PDGF), and the increased production of fibroblast growth (FGF) factor in
endothelial cells [Haberstroh et al. 1993]. TGF-  also stimulates the production of
connective tissue growth factor (CTGF) [Grotendorst 1997], which is thought to be a key
profibrotic growth factor in the development of renal fibrosis [Ito et al. 1998].  In
addition to its growth stimulatory and profibrotic properties, TGF-  is also an anti-
inflammatory molecule, as it inhibits T and B cells and their production of several
cytokines, such as IL-1, IL-2 and TNF-  [Border and Noble 1994].
TGF-  is thought to play a key role in different fibrotic kidney diseases, such as diabetic
nephropathy, chronic glomerulonephritis, and hypertensive glomerular injury [Border and
Noble 1997, Ziyadeh 2004]. Increased expression of TGF-  can be seen in these
conditions in both renal biopsy specimens and urine [Yamamoto et al. 1996, Honkanen et
al. 1997, Korpinen et al. 2000]. Interstitial fibrosis is a key feature of chronic allograft
nephropathy, and a wealth of experimental and clinical evidence supports a role for TGF-
 in the process of CAN [Shihab et al. 1995, Sharma et al. 1996, Shihab et al. 1996,
Cuhaci et al. 1999, Nicholson et al. 1999]. Similarly, the histopathological changes seen
in both cyclosporine and tacrolimus nephrotoxicity are thought to be associated with
increased expression of TGF- , which is directly caused by calcineurin inhibitors
[Shehata et al. 1995, Shihab et al. 1997a, Shihab et al. 1997b, Khanna et al. 1999].
4.2.2. Platelet- derived growth factor (PDGF)
Platelet- derived growth factor exists as a disulfide- linked homo- or heterodimer of two
polypeptide chains (A and B chain), and can form three different isoforms, PDGF-AA,
AB and BB, which all are biologically active [Heldin and Westermark 1999]. Their
biological actions are exerted by PDGF receptors  and . PDGF  receptor binds only
PDGF-B chains, while PDGF  receptor binds both A and B chains. PDGF-C and D have
been recently identified, but their exact biological role is not fully elucidated [Floege et
al. 2003, Li and Eriksson 2003]. PDGF is an important stimulatory growth factor for
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connective tissue cells, stimulating the chemotaxis and proliferation of fibroblasts and
smooth muscle cells. It also stimulates the chemotaxis of neutrophils and macrophages,
and their production of several other growth factors. Furthermore, PDGF stimulates the
production of several extracellular matrix proteins.
PDGF plays an important role in the embryogenesis of several tissues, such as kidney,
lung, and heart [Heldin and Westermark 1999]. In the kidney, overactivity of PDGF has
been associated with the pathogenesis of various glomerulonephritises characterized by
mesangial cell proliferation [Abboud 1995], tubulointerstitial fibrosis [Tang et al. 1996],
and also with kidney transplant rejection [Fellstrom et al. 1989, Alpers et al. 1996, Floege
et al. 2003, Savikko et al. 2003]. Some extent of interplay exists between TGF-  and
PDGF [Battegay et al. 1990] and at least a part of the effect of TGF-  on mesangial cells
may be mediated by PDGF [Haberstroh et al. 1993].
4.2.3. Others
Also several other molecules have been suggested to be important in the development of
CAN, of which the most important are described below.
Renin-angiotensin system (RAS) has a fundamental physiologic role in the regulation of
blood pressure, intravascular volume and electrolyte balance. Activation of the RAS and
generation of angiotensin II plays a role in the pathogenesis of hypertension and renal
fibrosis [Matsusaka et al. 1996], and inhibition of RAS by angiotensin converting
enzyme-inhibitors, or angiotensin II receptor blockers, is routine clinical practice in the
prevention of the progression of several kidney diseases. In addition to its hemodynamic
properties, angiotensin II is a growth factor, which upregulates adhesion molecules and
cytokines and promotes tissue fibrosis [Wolf and Neilson 1993]. Angiotensin II increases
the secretion of TGF-  and a part of its profibrotic effects are though to be mediated by
TGF-  [Border and Noble 1998]. Experimental and limited clinical evidence suggest that
blocking RAS in kidney transplant recipients may be beneficial in the long term in
preventing CAN and cyclosporine nephrotoxicity [Shihab et al. 1997c, Campistol et al.
1999, Szabo et al. 2000, Lin et al. 2002, Artz et al. 2004], supporting a role for
angiotensin II in the development of CAN.
The generation of pathological renal fibrosis is a complex process, in which also the
inhibition of extracellular matrix degradation may be important [Rerolle et al. 2000].
Plasminogen activator inhibitor type-1 (PAI-1) inhibits extracellular matrix degradation
by several mechanisms. One mechanism, by which TGF-  and angiotensin II promote the
generation of fibrosis, is the induction of the synthesis of PAI-1 [Kanalas and Hopfer
1997, Rerolle et al. 2000]. Evidence has associated increased expression of PAI-1 with
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several fibrotic kidney diseases [Rondeau et al. 1990, Yamamoto et al. 1996], and
increased expression of PAI-1 has been documented also in chronic allograft nephropathy
[Tang et al. 1998, Grandaliano et al. 2001, Lahlou et al. 2002].
Endothelin-1 (ET-1) is a peptide with potent vasoconstrictor actions and it is also a
stimulating growth factor for smooth muscle cells [Schiffrin 2001]. ET-1 has been
associated with the pathophysiology of various conditions and is also thought to be one of
the key players in renal fibrosis [Chatziantoniou and Dussaule 2005]. Increased levels of
ET-1 have been associated with chronic vasculopathy in kidney allografts and increased
expression of ET-1 has been documented also in tubular cells in acute and chronic
rejection of kidney transplants [Simonson et al. 1998, Chareandee et al. 2000]. In
experimental models, ET-1- receptor antagonists have prevented the development of
CAN [Orth et al. 1999], supporting a role also for ET-1 in the development of CAN.
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5. CYTOMEGALOVIRUS (CMV)
Cytomegalovirus (CMV) is a member of the betaherpesvirus subfamily, belonging to the
family of herpesviruses [Mocarski and Courcelle 2001]. Human cytomegalovirus is a
large DNA- virus of 150-200 nm in diameter, consisting of a linear double-stranded DNA
of approximately 230 kbp inside an icosahedral capsid, surrounded by tegument or
matrix, enclosed in an envelope of lipid bilayer carrying viral glycoproteins. Monocytes,
macrophages, lymphocytes, and hematopoietic precursor cells are the main cell types of
CMV infection and replication. In addition, CMV is able to infect several tissues,
including most of the parenchymal organs, salivary glands, eye, gastrointestinal and
genitourinary tract, and is also able to replicate in several cell types, including epithelial
cells, endothelial cells, fibroblasts, smooth muscle cells and macrophages [Pass 2001].
The cellular receptor of CMV remains yet to be fully elucidated but due to the wide range
of cells CMV is able to infect, the receptor is thought to be widely distributed [Mocarski
and Courcelle 2001]. One suggested candidate is epidermal growth factor receptor [Wang
et al. 2003]; others include cellular integrins [Feire et al. 2004]. Primary infection of
CMV occurs commonly in childhood or during the first two decades of life. Primary
infection is usually asymptomatic in an immunocompetent host but may present as a
mononucleosis-like syndrome, or rarely as hepatitis or pneumonia [Pass 2001]. During
primary infection and reactivations, viral shedding can be detected in saliva, breast milk,
semen, and other body excretions for weeks to months. The seroprevalence of CMV
varies between 40 and 100% in different countries, being approximately 70-80% in
Finland and Scandinavian countries, whereas in the United Kingdom the seroprevalence
of CMV is only approximately 40% [Ho 1990]. As with other members of the
herpesvirus family, primary CMV infection leads to a life-long latency. During latency,
the main reservoir of CMV is thought to be blood leucocytes, mainly mononuclear cells,
but also hematopoietic progenitor cells have been documented to carry latent viral DNA
[Taylor-Wiedeman et al. 1991, Kondo et al. 1994, Sindre et al. 1996, Soderberg-Naucler
et al. 1997]. During latency, CMV can be transmitted via blood products and transplanted
organs. Cell-mediated immunity with both natural killer cells and cytotoxic T
lymphocytes, is thought to be the most important defense mechanism to control CMV
infection and humoral immunity may be of less importance [Harari et al. 2004]. In an
immunocompromised host, either in individuals receiving immunosuppressive
medication or in HIV infected individuals, CMV can activate from latency and can cause
severe life-threatening infections.
5.1. CMV in Transplant Recipients
Cytomegalovirus is one of the most important pathogens in transplant recipients
receiving immunosuppressive medication. Most of the CMV infections in these
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individuals are caused by reactivation of latent virus of either recipient or donor origin. In
transplant recipients with no previous history of CMV infection, primary infection occurs
commonly and is often more severe compared to a reactivation of the virus in a
seropositive host. CMV infection in organ transplant recipients manifests commonly as
fever, malaise, leucopenia, or thrombocytopenia, but can also cause organ specific
manifestations, such as hepatitis, gastrointestinal symptoms, renal dysfunction, and CMV
pneumonitis, which still in the modern era of effective antiviral medication may be fatal.
Diagnosis of CMV infection in organ transplant recipients is based on detection of the
virus in blood, urine, biopsies, or bronchoalveolar lavage fluid. Shell vial cultures can be
used to detect the virus in blood or urine [Gleaves et al. 1984] but a quantitative assay for
the detection of CMV pp65 antigen in blood, developed in the late 1980s [van der Bij et
al. 1988], is more sensitive and accurate [The et al. 1995]. Nowadays quantitative PCR to
detect CMV DNA in the blood is the most common method to diagnose CMV infections,
being less time-consuming and more specific [Pang et al. 2003, Boeckh et al. 2004,
Piiparinen et al. 2004]. CMV proteins or genome can be demonstrated also in tissue
sections of biopsy material. Serology has an important role prior to transplantation in
evaluating the donor and recipient but after transplantation, serology has only a limited
diagnostic value.
Symptomatic CMV infection occurs in 10-50% of organ transplant recipients, depending
on the transplanted organ, and asymptomatic viral activation can be detected in the
majority of recipients [Patel and Paya 1998]. CMV infection can be treated with a
specific antiviral agent, the nucleoside analogue ganciclovir, which prevents viral
replication but does not completely eliminate the virus. In case of ganciclovir treatment
failure, or side effects, such as leucopenia, intravenous foscarnet may be used to treat
CMV infections. In kidney transplant recipients, the use of foscarnet is restricted by its
nephrotoxicity. Because of the high morbidity, costs, and even mortality associated with
CMV, high-risk groups of seronegative recipients of an organ from a seropositive donor
commonly receive prophylaxis with peroral valganciclovir, a valine ester of ganciclovir,
during the first 3-6 months after transplantation. Another strategy is preemptive
treatment, in which patients are frequently monitored and antiviral therapy is
administered when evidence of CMV viremia is detected, before clinical symptoms
develop. In addition to the symptomatic infection caused by CMV, several studies
indicate that CMV enhances the development of chronic rejection in heart, lung, and liver
transplantations [Grattan et al. 1989, Loebe et al. 1990, Arnold et al. 1992, Koskinen et
al. 1993, Kroshus et al. 1997, Lautenschlager et al. 1997a, Evans et al. 1999, Valantine et
al. 1999].
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 5.2. CMV in kidney transplantation
 After kidney transplantation, approximately 10-20% of recipients suffer from
symptomatic CMV infection [Patel and Paya 1998, Becker et al. 2002, Sagedal et al.
2002]. CMV seronegative recipients of an organ from a seropositive donor are at highest
risk of symptomatic CMV infection. Asymptomatic activation of the virus can be
detected in up to 60% of recipients [Sagedal et al. 2000]. Several studies have associated
acute CMV infection with glomerulopathic changes [Richardson et al. 1981, Tuazon et
al. 1987, Rao et al. 1994]. Evidence has also associated CMV with inferior graft survival
[Fryd et al. 1980, Rubin et al. 1985, Lewis et al. 1988, Almond et al. 1993, Hirata et al.
1996] and with acute rejections [Simmons et al. 1970, von Willebrand et al. 1986,
Pouteil-Noble et al. 1993, Reinke et al. 1994, Toupance et al. 2000, Sagedal et al. 2002].
Several recent studies have similarly associated CMV with chronic graft dysfunction and
graft loss [Humar et al. 1999, Giral et al. 2001, Tong et al. 2002, Geddes et al. 2003, Sola
et al. 2003, Nett et al. 2004, Sagedal et al. 2004], but contradictory data have also been
reported [Akposso et al. 1997, Dickenmann et al. 2001, Ricart et al. 2005]. Table 1
summarizes the clinical evidence of CMV and chronic allograft nephropathy or chronic
renal allograft dysfunction.
In addition to the suggested association between CMV and impaired graft survival, CMV
has been associated with increased cardiovascular complications [Humar et al. 2000,
Kalil et al. 2003], increased gastrointestinal complications [Kaplan et al. 1999, Sarkio et
al. 2005], and with the development of post-transplant diabetes mellitus after kidney
transplantation [Hjelmesaeth et al. 2004].
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Table 1. The role of CMV in CAN during the era of modern immunosuppression: clinical
evidence for and against CMV
For CMV: N Description
Nett et al 2004 2740 In univariate analysis, CMV disease was a risk factor for
graft loss (included also kidney-pancreas recipients, follow-
up 2-10 years)
Humar et al 1999 1339 In multivariate analysis, CMV disease was a risk factor for
biopsy proven chronic rejection only in the presence of
previous acute rejection (biopsies taken only when chronic
rejection suspected, follow-up 1-10 years)
Giral et al 2001 303 In a study comparing mycophenolate mofetil and
azathioprine, CMV disease was associated with poorer graft




496 Asymptomatic CMV infection and CMV disease were risk
factors for mortality and uncensored graft loss but not for
death-censored graft loss (prospective study, weekly
monitoring of CMV, follow-up 4-7 years)
Sola et al 2003 259 CMV disease but not asymptomatic CMV, was a risk factor
for CRAD in multivariate analysis (weekly monitoring of CMV
between days 30-90 post-transplantation, follow-up 0.5-4
years)
Geddes et al 2003 41 CMV infection and disease were associated with inferior
renal function at one year post-transplantation
Tong et al 2002 37 CMV disease was associated with poor graft function at 6
months and with CAN (biopsies taken only when CAN was




169 Preemptive therapy with ganciclovir was administered, when
CMV viremia was detected. CMV infection had no impact on
graft survival or renal function (follow-up 0-6 years)
Ricart et al 2005 205 In simultaneous kidney-pancreas recipients, CMV infection
was associated with inferior renal function 1-3 months post-




84 CMV infection was not associated with inferior graft function
or survival (CMV monitoring every 1 to 2 weeks, follow-up 5
years)
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5.3. CMV and transplant rejection in experimental and molecular level
In experimental rat models of chronic kidney allograft rejection, CMV increases
inflammation, enhances the development of vascular changes, and increases the
generation of fibrosis [Yilmaz et al. 1996, Lautenschlager et al. 1997b, van Dam et al.
2000, Inkinen et al. 2002]. In addition, increased expression of adhesion molecules
(ICAM-1, VCAM-1) and growth factors (TGF- , PDGF, CTGF) was associated with
CMV infection [Yilmaz et al. 1996, Kloover et al. 2000, Inkinen et al. 2005]. On the
molecular level, several possible mechanisms exist by which CMV may increase the
alloresponse and development of chronic changes. CMV is able to infect several cell
types in the kidney [Heieren et al. 1988a, Heieren et al. 1988b, Ustinov et al. 1991].
CMV directly or indirectly induces the production of several proinflammatory cytokines,
such as IL-1, IL-2, TNF-  [Iwamoto et al. 1990, Geist et al. 1991, Smith et al. 1992],
adhesion molecules  (ICAM-1,  VCAM-1) [van Dorp et al. 1993, Sedmak et al. 1994,
Craigen and Grundy 1996], and growth factors (TGF- , PDGF) [Michelson et al. 1994,
Yoo et al. 1996, Srivastava et al. 1999, Zhou et al. 1999], which are all thought to be
important in the process of allograft rejection and chronic allograft nephropathy.
Chemokines are also important mediators of inflammation in organ transplant
pathophysiology. In addition to upregulating the production of several chemokines during
infections, the CMV genome encodes chemokine analogues and chemokine receptor
analogues, through which the virus is able to further modify immune response and to
stimulate cellular responses [Bodaghi et al. 1998, Streblow et al. 1999, Vink et al. 1999].
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AIMS OF THE STUDY
The aim of this study was to investigate and clarify the role of cytomegalovirus in the
process of chronic allograft nephropathy in clinical kidney transplantation and to study
the pathogenetic mechanisms of this suggested association.
The specific objectives were to study:
1. the impact of cytomegalovirus infections and the presence of CMV in the allograft on
the development of histopathological changes in six months protocol biopsies (I).
2. the urinary excretion of molecules thought to be important in the development of
chronic allograft nephropathy during cytomegalovirus infections (II).
3. the impact of persistent CMV infection in the graft on the expression of cytokines,
adhesion molecules and growth factors thought to be important in the development of
chronic allograft nephropathy (III).
4. the impact of persistent intragraft CMV infection on long-term kidney allograft




Altogether 1451 adult renal transplantations were performed between the years 1992-
2000, and 394 of these patients remained at follow- up at the Helsinki University
Hospital Department of Medicine, Division of Nephrology. Primary immunosuppression
therapy consisted mainly of cyclosporine, azathioprine and methylprednisolone. No anti-
viral prophylaxis for CMV or other herpesviruses was routinely given post-operatively.
Trimethoprim-sulfametaxazole prophylaxis against pneumocystis carinii was given
routinely during the first six months after transplantation or, if the level of serum
creatinine was more than 200 mol/l, pentamidine inhalations were usually used instead.
All the patients in this study had a clinical suspicion of CMV infection and samples taken
for the diagnosis of CMV.
2. Acute rejections (I-IV)
Acute rejections were diagnosed by fine-needle aspiration biopsy [Hayry and von
Willebrand 1981] and/or biopsy histology and by clinical criteria. Biopsy histology was
analyzed according to the Banff classification [Solez et al. 1993, Racusen et al. 1999].
Recipients suffering from clinically significant acute rejections received treatment with
high-dose intravenous methylprednisolone and, on demand, additionally with OKT3
and/or plasmapheresis.
3. CMV infections
3.1. Detection of CMV infection (I-IV)
The patients in this study were not regularly monitored for CMV and samples for the
detection of CMV were obtained only when clinical signs of infection were observed
(fever, unexplained increase of serum creatinine, leukopenia, thrombocytopenia,
hepatopathy, gastroenteritis, pneumonia). CMV infection was diagnosed by the standard
pp65 antigenemia test [The et al. 1995] and rapid shell vial cultures from blood and/or
urine [Lautenschlager et al. 1989]. Infections were treated on clinical indications with
intravenous ganciclovir. Recipients with CMV infection who received no ganciclovir
treatment, demonstrated only occasional low level antigenemia, which subsided during
follow-up.
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3.2. Demonstration of CMV from the biopsies (I, III-IV)
CMV antigens were detected in kidney allograft biopsies using a monoclonal antibody
against CMV specific protein pp65 (Biotest, Dreieich, Germany) and indirect
immunoperoxidase staining. The biopsy material was snap-frozen and 3-4 micron thick
sections were cut, acetone fixed and stored at -20 C until used. Before staining, the
sections were treated with chloroform to avoid nonspecific reactions with endogenous
peroxidase. The presence of CMV in kidney allograft biopsies was also demonstrated by
DNA hybridization in situ using a biotinylated probe (Enzo Biochem Inc., New York,
NY) prepared from a mixture of two clones of CMV sequences in the BamHI site of
pBR22 [Lautenschlager et al. 1997a]. To visualize the anatomic structures in the kidney,
Mayer’s hemalum was used as a counterstain in both the immunoperoxidase stainings
and DNA hybridizations in situ.
4. Biopsy technique (I-IV)
Six months biopsies were performed under ultrasound guidance with either Bard
Magnum® or Bard Biopty® devices and 18 gauge Biopty-cut® needles®.
According to the policy of our clinic, two biopsies were taken: one piece was
embedded in Historesin (Leica Instruments GmbH, Heidelberg, FRG) while the
other was sectioned for immunofluorescence and the remainder deep frozen at -80C. For
light microscopy, serial tissue sections were stained with hematoxilin and eosin,
PAS, methenamine silver, and May-Grünwald-Giemsa.
5. Biopsy histology (I-III)
According to the policy of our clinic, a protocol biopsy six months after transplantation
was performed for every recipient. The following histological parameters were
retrospectively analyzed for the purpose of this study according to the Banff ’97
classification [Racusen et al. 1999]: tubulitis and interstitial inflammation as indicators of
acute inflammatory response, and glomerular mesangial matrix increase, allograft
glomerulopathy, tubular atrophy, interstitial fibrosis and vascular fibrointimal thickening
as indicators of chronic allograft damage. Special attention was focused on the analysis of
vascular changes and vascular intimal thickening was further specified as arterial or
arteriolar. Each vessel identified in the biopsy specimen was scored independently and
the average score was recorded.
6. Urine specimens (II)
Urine samples for CMV culture were collected when CMV infection was clinically
suspected or when urine samples were collected for other reasons, such as controlling of
proteinuria or bacteriuria. Urinary concentrations of TGF-β1 and soluble ICAM-1
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(sICAM-1) were measured by sensitive enzyme immunoassays (EIA) [Honkanen et al.
1997] (Bender MedSystems, Vienna, Austria for sICAM-1), and radio immunoassay
(RIA) was used to measure urinary excretion of TNF-α [Teppo and Maury 1987].
Pharmacy albumin RIA was used to measure urinary albumin. The excretions of the
analyzed molecules were related to concomitant urinary creatinine content (millimoles).
7. Immunohistochemistry (III)
The expression of TGF-β1, PDGF-AA, PDGF-BB, ICAM-1, ELAM, VCAM-1, IL-2
receptor, CD4, CD8, and MHC class II antigen were demonstrated in frozen sections (3-5
µm thick) of the kidney allograft biopsies by indirect immunoperoxidase staining.
Monoclonal antibodies were used for ICAM-1, VCAM-1, ELAM-1 (R&D Systems,
Abignon, UK), IL-2R (Becton Dickinson Immunocytometry Systems, San Jose, USA)
CD4, CD8 (Southern Biotechnology Associates, Inc, Birmingham, USA), and MHC class
II (DAKO A/S, Clostrup, Denmark) and polyclonal antibodies for TGF-β1, PDGF-AA,
and PDGF-BB (R&D Systems, Abignon, UK). Expression was scored semiquantitatively
on a scale from 0 to 3 or by counting positive leukocyte cells per high power visual field
(in the case of IL-2R, CD4, and CD8). All biopsies were scored by two researchers.
Expression was scored separately in tubuli, glomeruli, arterial and peritubular capillary
endothelial cells and in vascular smooth muscle cells.
8. Clinical variables (I-IV)
Kidney allograft function was measured as the level of serum creatinine (I-IV) and
creatinine clearance (ml/s/1.73m2) was measured from 24 hour urine collection (I) or was
calculated from serum creatinine, age, gender, and body weight using the Cockcroft-
Gault- formula [Cockcroft and Gault 1976] (IV). In addition, the amount of protein in
24h urine collection was determined (I).
The following baseline data at the time of transplantation were obtained from patient
files: recipient and donor age and gender, primary renal disease, number of HLA-A, B,
and DR mismatches, cold ischemia time, onset of graft functions (days post-
transplantation). Systolic and diastolic blood pressure and blood trough level of
cyclosporine A, glycosylated haemoglobin, and total serum cholesterol values were
obtained from the patient files at six months (I, III), at the time of the urine sample (II), or
annually after transplantation (IV).
9. Statistical methods (I-IV)
All data are expressed as mean±1 standard deviation, unless otherwise indicated.
Differences between two groups in the distribution of continuous variables were analyzed
with the nonparametric Mann-Whitney U-test and differences between the three groups
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were analyzed with the nonparametric Kruskal-Wallis one-way analysis. Nonparametric
tests were chosen because all distributions were not normal and because of small sample
size (I-IV). Graft survival probabilities were estimated by the Kaplan-Meier method, and
differences between two or more groups were analyzed by the log rank test. Univariate
Cox regression analysis was used to calculate relative risks (RR) and 95 % confidence
intervals (CI) of graft failure. Graft survival was analyzed both uncensored for death, i.e.
death with a functioning graft was considered as an event and censored for death, i.e.
deaths with functioning grafts were censored. For logistic regression analyses, creatinine
clearance values were converted to binary and used as outcome variables. The median
was used as a cut point to obtain two categories. For multivariate analyses, the three most
significant variables in univariate analysis were chosen (IV).
The calculations were performed with StatView (I) (version 512+, Brainpower Inc.,
Calabasa, CA) and SPSS statistical software (II-IV) (version 12.0.1., SPSS Inc, Chicago,
IL). Two tailed P-values lower than 0.05 were considered statistically significant.
35
RESULTS
From the patients who remained at follow-up at Helsinki University Hospital between the
years 1992-2000, 172 patients had a suspicion of CMV infection and CMV was
diagnosed in 82 recipients. The control group comprised 23 patients with no evidence of
CMV infection despite several samples taken at different time points after
transplantation. Patients included in the study are described in figure 3.
Figure 3. Description of the patients included in the studies I-IV.
172 patients, transplanted during 1992-2000 had a suspicion of CMV infection.
CMV was diagnosed in 82 patients. Control group comprised 23 patients, in whom CMV
was not found despite several samples taken at different time points after transplantation
I. Frozen biopsy material from 6
months protocol biopsies was available
for the demonstration of CMV antigens
and DNA from 41 patients with
previous CMV infection and from 11
patients free of CMV.
II. Urine samples taken during CMV
infection were available from 13
patients, and also from 8 patients free
of CMV infection.
IV. Frozen biopsy material from biopsies taken after CMV infection was available for the
demonstration of CMV antigens and DNA from 48 recipients with previous CMV infection.
Frozen biopsy material was also available from 15 recipients with no evidence of CMV
infection. Follow-up data from 5 years after transplantation was analyzed.
III. Frozen biopsy material for further immunohistochemical analyses was available from
16 patients with previous CMV infection and from 5 patients with no evidence of CMV
infection.
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1. Intragraft CMV and histopathological changes (I)
Histopathological changes were scored from 6-month protocol biopsy specimens from
52 renal allograft recipients, from whom frozen biopsy material from the protocol
biopsies was available for the demonstration of CMV pp65 antigens and DNA
hybridization in situ. All patients had a clinical suspicion of CMV infection and had
samples taken for the detection of CMV infection. In 18 of the 41 patients with CMV
infection, CMV antigens or DNA were found in the 6-month protocol biopsy specimens.
Of these 18 patients with intragraft CMV, 11 suffered from several episodes of CMV
infection. The control group comprised 11 patients, in whom CMV was not diagnosed
despite several samples taken at different time points after transplantation. No CMV
DNA or proteins were found in the biopsies of these 11 patients.
No differences in the histopathological parameters analyzed were recorded in patients
with previous CMV infection (N=41) compared to patients free of CMV infection
(N=11). However, in the biopsies of patients with a positive CMV finding by
immunohistochemistry or DNA in situ hybridization (N=18), the intensity of fibrous
intimal thickening in the small arterioles was significantly increased compared to
recipients with no history of CMV infection (p<0.01). No differences in the other
histopathological parameters were found. Acute rejection developed in 22 of the 41
patients with CMV infection and in 6 of 11 recipients free of CMV infection (p=non
significant, ns). No differences were found in the severity or the number of acute
rejection episode between the recipients with CMV infection and no CMV infection. No
differences were found in the pretransplant CMV antibody status between the patients
with intragraft CMV and patients with no previous CMV.
When the study patients were further analyzed with regard to acute rejections, no
differences in vascular or other histopathological changes were found in the subgroup of
patients without previous acute rejection episodes, despite their CMV status. In patients
free of CMV infection, previous acute rejection episodes were not associated with
increased vascular or other histopathological changes. However, in recipients with acute
rejections as well as a positive CMV finding in the graft, the intima of the small arterioles
was significantly thickened as compared to recipients without CMV infection (p<0.05)
(Figure 4). The groups of patients with previous CMV infection, intragraft CMV, or no
previous CMV, did not differ in renal function parameters.
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Figure 4. Small occluded arterioles (arrows) in a biopsy of a patient with both a positive
CMV finding in the graft and a previous history of acute rejection.
2. Urinary excretion of soluble molecules during CMV infection (II)
Urine samples from 46 renal transplant recipients were available for this study. Samples
were taken due to suspicion of CMV infection, acute rejection, or controlling of
proteinuria or bacteriuria. Urine samples taken from patients with previous CMV
infection (n= 22) or CMV infection after the urine sample (n=3), were excluded from the
analysis. Thirteen patients had CMV infection at the time of the urine sample (CMV
group), as demonstrated by a positive antigenemia test in 10 patients and in 3 patients by
a positive culture from urine. The 8 patients in whom CMV infection was not diagnosed
at any time point were used as controls. The two study groups did not differ in any of the
demographic factors analyzed.
The urinary excretion of TGF-β1 was significantly higher in the urine samples taken
during a CMV infection CMV (N=13) compared to controls with no evidence of previous
or ongoing CMV infection (N=8) (p<0.001) (Table 2). No differences were recorded
between the CMV group and the controls in the excretions of other cytokines analyzed or
of albumin. At the time of the urine sample, 3 patients from the CMV group and 3
patients from the control group, suffered from acute rejection. Ongoing acute rejections
were not associated with increased excretion of the molecules analyzed. None of the pre
or perioperative factors, time of the urine collection after transplantation, serum
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creatinine, blood trough levels of cyclosporine, previous acute rejections, nor the amount
of proteinuria, had any correlation with urinary excretion of any of the molecules
analyzed.
In the 13 patients with a positive history of CMV infection and increased urinary levels
of TGF-β1, a significantly higher degree of interstitial fibrosis was recorded in the six
months protocol biopsies (P<0.01). Tubular atrophy was also somewhat increased in
patients with previous CMV, although not statistically significantly. No differences
existed in the other histopathological parameters analyzed. Previous acute rejection
episodes were not associated with increased histopathological changes in any of the
parameters analyzed. Urinary excretion of TGF-β1 correlated positively, although not
statistically significantly, with the degree of interstitial fibrosis (R=0.43, p=0.08).
Table 2. The impact of CMV infections on the urinary excretion of S-ICAM –1, TNF- α,
and TGF- β1. All data expressed as mean±SD. *p < 0.001.
3. Persistent CMV in the allograft (III-IV)
Frozen biopsy material from biopsies taken after CMV infection were available from
48/82 patients for the demonstration of CMV antigens or DNA in the biopsies. Frozen
biopsy material was available for the demonstration of CMV also from 15 patients with
no evidence of previous CMV infection, despite several samples taken at different time
points after transplantation. These 63 recipients were further analyzed. In 17/48 patients
with a positive history of CMV infection, CMV persisted in the biopsy, as CMV antigens
or DNA were demonstrated in the allograft biopsies 2-12 months after the last positive
finding in blood or urine (persistent CMV group). In 31/48 recipients with previous CMV
infection, and also in the 15 patients free of CMV, no CMV DNA or antigens were found
in the biopsies (non-persistent CMV and no CMV groups respectively). No differences
were found in the number or severity of acute rejection episodes or in the pretransplant
CMV antibody status between patients with persistent intragraft CMV compared to the
other groups. Of the biopsies analyzed, 12/17 were protocol biopsies in the persistent
CMV group, 22/31 in the non-persistent CMV group, and 9/15 in the no CMV group




S-ICAM- 1 (ng/mmol) 144.1 ± 97.2 275.0 ± 363.2
TNF- α (ng/mmol) 0.49 ± 0.35 0.33 ± 0.32
TGF- β1 (ng/mmol) 13.3 ± 6.7 51.1 ± 28.0*
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(p=ns). No significant differences between the study groups were recorded in the time of
the biopsy sample after transplantation.
3.1. Immunohistochemical analyses (III)
Frozen biopsy material for the immunohistochemical stainings was available for further
analyses from 11 patients with persistent intragraft CMV, from 5 patients with non-
persistent CMV, and from 5 patients free of CMV infection. In the immunohistochemical
analyses, the expression of TGF-β1 was significantly increased in arterial endothelial cells
in patients with persistent intragraft CMV, compared to patients with no CMV (p=0.036).
Similarly, the expression of PDGF-AA was significantly increased in tubuli (p=0.040)
and the expression of ICAM-1 in peritubular capillary endothelium (p=0.003) in patients
with persistent CMV in the graft, compared to patients free of CMV (table 3). No
differences were recorded in the expression of the other molecules analyzed between the
groups. Previous acute rejection episodes were not associated with increased expression
of any of the molecules analyzed in the immunohistochemical stainings.
In the patients with persistent CMV and increased intragraft expression of TGF-β1,
PDGF-AA and ICAM-1, analysis of the 6- month protocol biopsy histology showed a
higher degree of arterial intimal thickening compared to patients who were free of CMV
infection (P=0.02). No differences were found in the other histopathological parameters
analyzed.
Table 3.  The impact of persistent CMV infection on the expression of TGF-β1, PDGF-AA





Controls (n=5) 0.5 ± 1 0 ± 0 0 ± 0
Persistent CMV (n=11) 1.3 ± 1 0.5 ± 0.8 1.0 ± 1.2*
PDGF-AA
Controls (n=5) 0.5 ± 0.6 0.8 ± 1.0 0.5 ± 0.6
Persistent CMV (n=11) 1.6 ± 0.9** 1.4 ± 1.0 0.9 ± 0.8
ICAM-1
Controls (n=5) 0 ± 0 1.6 ± 0.5 0.5 ± 0.6
Persistent CMV (n=11) 0.3 ± 0.9 2.8 ± 0.4*** 0.3 ± 0.9
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3.2. Long- term graft function and survival (IV)
Graft survival (uncensored for death) in patients with persistent intragraft CMV was
significantly reduced compared to patients with non-persistent CMV or no CMV
(P=0.049). A similar trend was seen in death-censored graft survival (P=0.11, NS). When
patients with persistent CMV in the graft were compared to patients with no evidence of
intragraft CMV (i.e. non-persistent CMV and no CMV groups combined), persistent
CMV was associated with significantly reduced graft survival both uncensored for death
and death-censored (P=0.020 and P=0.041 respectively) (Figure 5).
In Cox regression analyses including several pre or postoperative risk factors for graft
loss, persistent intragraft CMV infection was the only significant risk factor for graft loss,
uncensored for death (relative risk 3.5, 95% confidence interval 1.1–10.9, P=0.030). The
only significant risk factor for death-censored graft survival was the number of HLA-
mismatches (RR 5.0, P=0.028), although borderline increased risk was also associated
with persistent intragraft CMV (RR 5.3, P=0.068).
Kidney allograft function, as measured by estimated creatinine clearance, was
significantly reduced in patients with persistent intragraft CMV compared to non-
persistent and no CMV groups at one and two years (at one year 0.89±0.32 vs. 1.16±0.31
and 1.05±0.26 ml/s/1.73m2 respectively, P=0.018 and at two years 0.84±0.32 vs.
1.12±0.31 and 0.99±0.35 ml/s/1.73m2, P=0.012). In univariate logistic regression
analyses, persistent CMV and higher donor age showed to be the only significant risk
factors for lower clearance one year after transplantation (OR 7.69 for CMV, P = 0.004,
OR 1.06 for one year increase in donor age, P=0.014). Similarly, in multivariate logistic
regression analysis, persistent intragraft CMV and higher donor age appeared as
independent risk factors for lower clearance one year after transplantation (OR 4.4 for
CMV, P=0.027, and OR 1.04 for one year increase in donor age, P=0.049). At two years,
persistent CMV was the only significant risk factor for lower clearance in univariate
analysis (OR 4.3, P=0.026) and the only significant independent risk factor for lower
clearance two years after transplantation in multivariate analysis (OR 4.9, P=0.020). No
differences existed in the creatinine clearance values at three to five years after
transplantation between the persistent CMV group and the other groups.
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Figure 5. Reduced graft survival (uncensored for death) (P=0.020) and death- censored
graft survival (P=0.041) in patients with persistent CMV compared to patients with non-
persistent or no CMV.
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DISCUSSION
Cytomegalovirus is an important pathogen infecting organ transplant recipients. In
addition to the complications associated with acute infection, CMV is a suggested risk
factor for chronic rejection after solid organ transplantation. The best clinical evidence
supporting this hypothesis derives from heart transplantation [Grattan et al. 1989, Loebe
et al. 1990, Koskinen et al. 1993, Valantine et al. 1999]. Some studies support a role for
CMV in the development of vanishing bile duct syndrome (chronic rejection) after liver
transplantation [O'Grady et al. 1988, Arnold et al. 1992, Lautenschlager et al. 1997a,
Evans et al. 1999], and obliterative bronchiolitis after lung transplantation [Kroshus et al.
1997]. The role of CMV in chronic allograft nephropathy after transplantation of the
kidney is more controversial. Most of the data on the association of CMV and CAN are
experimental; clinical evidence is still scarce and some studies have found no association
between CMV and CAN (see table 1). The aim of this study was to investigate the
possible association of CMV and CAN in humans in detail and also to study the
mechanisms involved.
1. CMV and renal allograft histopathology
 Although CMV infections after transplantation have been extensively studied,
surprisingly little data exist on the association of CMV infection with CAN, as defined by
histopathological changes in allograft. Most of the studies have only associated CMV
with clinical or laboratory parameters, and no systematic histological analyses have been
presented. In the present study, clinical CMV infection was not associated with any
histopathological changes in the graft. However, we found CMV antigens or DNA in
glomerular, tubular and vascular structures in 18/41 of the 6-month protocol biopsies of
kidney allograft recipients after CMV infection, and this intragraft CMV infection
seemed to be associated with increased vasculopathic changes in small arterioles. Further
analysis revealed that intragraft CMV infection was associated with increased
vasculopathic changes in small arterioles only together with a previous history of acute
rejection episodes (I). Neither acute rejection nor CMV in the graft alone was associated
with any histopathological changes.
CMV is able to infect several cell types in the kidney in cell cultures, including
glomerular, tubular and endothelial cells [Heieren et al. 1988a, Heieren et al. 1988b,
Ustinov et al. 1991]. Also in clinical kidney transplantation, the virus has been detected in
the allograft [Ulrich et al. 1986, Andersen et al. 1990, Lardelli et al. 1994, Holma et al.
2000, Liapis et al. 2003] and evidence shows that CMV is able to persist in the allograft
for months after viremia and active infection (III, IV) [Holma et al. 2000]. This
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persistence has been associated with chronic changes in the graft [Holma et al. 2000],
(III). Persistent viral infection in the graft may be able to stimulate inflammatory cells
both indirectly and also by direct effects of CMV on the production of several growth
factors and cytokines (III). This continuous injury in the graft, together with an additional
injury caused by a previous acute rejection episode, may have caused persistent low-level
inflammation, leading to growth factor stimulation and the development of vascular
changes, as seen in our study (I, III).
2. CMV and the mechanisms of CAN
The studies investigating the possible association of CMV and CAN are mainly based on
animal models. An association of rat CMV infection and chronic renal allograft rejection
has been described in several models [Yilmaz et al. 1996, Lautenschlager et al. 1997b,
van Dam et al. 2000]. In the rat, CMV infection increased inflammation, accelerated the
development of chronic vascular and fibrotic changes [Yilmaz et al. 1996,
Lautenschlager et al. 1997b, Inkinen et al. 2002] and was associated with increased
expression of several molecules, such as ICAM-1, VCAM-1, TGF- , PDGF, and CTGF,
which are all thought to be important in the development of chronic rejection [Yilmaz et
al. 1996, Kloover et al. 2000, Inkinen et al. 2005]. Clinical studies of the mechanisms
behind the suggested association of CMV and CAN mainly involve analyses of
proinflammatory cytokine levels [Kern et al. 1996, Nordoy et al. 2000a, Nordoy et al.
2000b, Tong et al. 2001].
2.1. CMV and proinflammatory cytokines and adhesion molecules
CMV modulates the immune response through several proinflammatory cytokines, and
reactivation of CMV from latency may be stimulated by cytokines produced during the
alloimmune response, such as TNF- , IL-1, and IFN-  [Soderberg-Naucler and Nelson
1999, Hummel and Abecassis 2002].The key cytokine in the association of CMV and the
rejection cascade is suggested to be tumor necrosis factor –  (TNF- ) [Smith et al. 1992,
Docke et al. 1994, Fietze et al. 1994]. CMV directly upregulates the production of TNF-
 in monocytes and macrophages [Smith et al. 1992] and on the other hand, TNF-
stimulates the activity of CMV via the direct actions of transcription factor NF- B on the
viral genome [Fietze et al. 1994, Prosch et al. 1995]. This bidirectional mechanism may
enhance alloresponse and injury to the graft. In addition, CMV may directly stimulate the
production of IL-1 in mononuclear cells [Iwamoto et al. 1990]. These cytokines IL-1 and
TNF-  in turn stimulate the synthesis and release of growth factors TGF-  and PDGF
[Phan et al. 1992, Pintavorn and Ballermann 1997, Funayama et al. 1998], which are
associated with the pathobiology of CAN. CMV also directly stimulates the production of
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IL-2 and IL-2 receptor, which are important molecules in the alloimmune response [Geist
et al. 1991].
Proinflammatory cytokines IL-1 and TNF-  also stimulate the expression of adhesion
molecules ICAM-1 and VCAM-1, which are key adhesion molecules in the alloimmune
response and have also been associated with chronic changes. In experimental studies,
CMV is able to directly stimulate the expression of ICAM-1 both in vitro and in vivo
[van Dorp et al. 1993, Craigen and Grundy 1996, Burns et al. 1999, Kloover et al. 2000].
Persistent intragraft CMV infection was, in our study, associated with increased
expression of ICAM-1 in the peritubular capillaries (III). As ICAM-1 is constitutively
expressed in transplanted kidneys with normal histology [Solez et al. 1997], some extent
of ICAM-1 was seen in all the biopsies analyzed. However, the expression was
significantly more intense in recipients with persistent intragraft CMV infection.
2.2. CMV and increased expression of TGF-
TGF-  is thought to be one of the key fibrogenic molecules in the development of CAN,
and it also has some vasculopathic potential, mostly mediated by increased expression of
PDGF. In vitro, CMV immediate early genes directly induce the secretion of TGF-  in
endothelial cells [Yoo et al. 1996]. In addition, proinflammatory cytokines IL-1 and
TNF- , which are directly stimulated by CMV, increase the production of TGF-  [Phan
et al. 1992, Pintavorn and Ballermann 1997].
In an experimental rat model of chronic renal allograft rejection, rat CMV infection
increased the expression of TGF-  and CTGF in the graft and increased collagen
synthesis and the degree of interstitial fibrosis [Inkinen et al. 2002, Inkinen et al. 2005].
CTGF is an important profibrotic growth factor in renal fibrosis [Ito et al. 1998], and
most of the profibrotic effects of TGF-  are thought to be mediated by increased
secretion of CTGF caused by TGF-  [Grotendorst 1997]. We found increased expression
of TGF-  in the allograft associated with persistent intragraft CMV infection (III), and
increased vasculopathic changes were recorded in recipients with persistent CMV
infection in the graft.
Increased urinary excretion of TGF-  has been described in several fibrotic kidney
diseases. Although most of the antibodies used to detect TGF-  are unable to differentiate
between active and latent form of TGF- , increased urinary levels of TGF-  are thought
to reflect increased production of the molecule and have been associated with
histopathological changes and prognosis [Honkanen et al. 1997, Korpinen et al. 2000],
also in renal transplant recipients [Boratynska 1999, Teppo et al. 2004, Rogier et al.
2005]. We found significantly increased urinary levels of TGF-  during CMV infection
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in kidney allograft recipients (II). This novel finding was associated with histologic
evidence of increased degree of interstitial fibrosis, indicating the clinical significance of
this observed increase in the production of TGF- . We hypothesize that CMV infection
may enhance the expression of TNF- , which in turn increases the production of TGF- ,
also directly stimulated by CMV. TGF-  is a profibrotic molecule and also mediates
some of its profibrotic effects by stimulating the expression of CTGF, leading to
increased collagen synthesis and fibrosis, as has been earlier observed in an experimental
model [Krogerus et al. 2003, Inkinen et al. 2005].
2.3. CMV and increased expression of PDGF
PDGF is an important stimulating growth factor for mesenchymal cells, and increased
expression of PDGF has also been associated with the development of chronic allograft
nephropathy [Fellstrom et al. 1989, Floege et al. 1998]. According to some studies
PDGF-BB, or actions mediated by PDGF receptor , is thought to be the most important
isoform in several pathogenetic states, such as atherosclerosis [Betsholtz and Raines
1997]. However, in chronic renal vascular rejection, PDGF-AA is expressed by intimal
and medial smooth muscle cells in arteries, whereas PDGF-BB is mostly expressed in
infiltrating monocytes [Floege et al. 1998]. In our study, increased expression of PDGF-
AA was observed in tubuli and also slightly in arterial endothelium of patients with
persistent intragraft CMV, whereas the expression of PDGF-BB was scarce and seen
mostly in the infiltrating inflammatory cells (III). In vitro studies show that CMV is able
to directly induce the production and secretion of PDGF in endothelial and smooth
muscle cells [Srivastava et al. 1999, Zhou et al. 1999]. Moreover, in an experimental rat
model of chronic allograft rejection, CMV infection was associated with increased
expression of PDGF [Inkinen et al. 2005]. These findings support our hypothesis of CMV
being able to stimulate the expression of PDGF and thus accelerate the progression of
CAN, recorded in our study as increased vascular changes (I, III).
3. CMV and long-term prognosis
In biopsies taken after CMV infection, CMV persisted in 17/48 of kidney grafts, i.e.
CMV antigens, DNA, or both, were found in the biopsy more than 2 months after the last
positive finding in blood or urine. Similar persistence of CMV in the graft has been
observed after liver transplantation and also in the kidney [Lautenschlager et al. 1997a,
Holma et al. 2000], but the nature and relevance of this persistence in the kidney is poorly
described. In our material, in addition to the histopathological changes, this persistence in
the kidney allograft was associated with significantly reduced graft function and survival
(IV).
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Previous studies of the association of CMV and CAN have only investigated the role of
CMV infection or disease as detected by viremia, and intragraft CMV status has not been
detected. We hypothesize that it is in particular the long-term injury caused by a
persistent CMV infection in the graft, which is associated with the development of
chronic allograft nephropathy. The intragraft CMV infection observed in our study could
explain the controversial results of previous CMV studies (table 1), since we found no
association between “transient” CMV infection and graft function, survival, or
histopathological changes. All significant differences were associated with CMV detected
in the allograft. Reduced kidney function was recorded only in recipients with persistent
intragraft infection (IV) but not in recipients with intragraft CMV infection only in the 6-
month protocol biopsies (I).
The incidence of intragraft CMV infection has not been studied prospectively, and this
retrospective study from an era before the current antiviral prophylaxis and preemptive
protocols, including only patients with a suspicion of CMV infection, is not sufficient to
answer the question of how common this intragraft infection with CMV is. Similarly, the
factors that might favour the persistence of CMV in the graft are largely unknown. In our
study, slightly increased donor age and HLA mismatch was seen in the baseline
characteristics of recipients with persistent CMV infection in the graft. Both of these
factors are able to increase the immunogenicity of the allograft; increased alloreactivity
may trigger the virus and favour the persistence of CMV.
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4. Conclusions
The findings of our study suggest that persistent CMV infection in the kidney allograft is
detrimental to long-term kidney allograft function and survival. In recipients with both
intragraft CMV infection and previous acute rejection episodes, increased vasculopathic
changes were recorded in small arterioles in 6-month protocol biopsies. Furthermore,
persistent CMV infection was associated with increased expression of adhesion molecule
ICAM-1 and growth factors TGF-  and PDGF, which are all thought to be important
molecules in the process of chronic allograft nephropathy. Similarly, urinary excretion of
TGF-  was increased during CMV infections. In five years follow-up, persistent CMV
infection was associated with reduced graft function and survival.
Figure 6. Schematic representation of the role of CMV in the pathogenesis of CAN.
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Based on these results, we hypothesize that persistent CMV infection in the kidney
allograft, especially in combination with other injuries to the graft, is able to cause
continuous injury to the allograft by increasing inflammatory and growth factor response,
resulting in arteriosclerotic changes and interstitial fibrosis, and finally manifesting as
reduced allograft function and survival. These novel findings of persistent intragraft
infection may explain the previous controversial results of the impact of CMV infection
on kidney allograft survival, since the effect persistence of CMV has not been
demonstrated in earlier reports. These results strongly suggest that effective prevention,
diagnosis, and treatment of CMV infections may be a major factor in improving the long-
term prognosis of kidney transplantation.
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